ANN ARBOR — Ann Arbor-based Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) said Thursday that it had received shareholder approval to change its corporate name to Synthetic Biologics Inc.
Synthetic Biologics is a pharmaceutical company developing therapeutics and medicines based on synthetic DNA. Company officials said the new name more accurately reflects the company’s business.
Company officials said it’s expected that the company’s shares will start trading under its new name and stock ticker symbol, “SYN,” on Thursday.
Synthetic Biologics’ common stock has been assigned a new CUSIP number of 87163U102 in connection with the name change. Outstanding stock certificates are not affected by the name change and will not need to be exchanged.
Synthetic Biologics is developing, or has partnered the development of, product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis.
More at www.syntheticbiologics.com.